Safety and Efficacy Field Study of Artesunate for Dogs with Non-resectable Tumours

Publication type:
Journal article
Metadata:
Autoren
  • Gerard R Rutteman
  • Suzanne A Erich
  • Jan A Mol
  • Bart Spee
  • Guy CM Grinwis
  • Lawrence Fleckenstein
  • Cheryl A London
  • Thomas Efferth
Autoren-URL
https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=fis-test-1&SrcAuth=WosAPI&KeyUT=WOS:000319233100005&DestLinkType=FullRecord&DestApp=WOS_CPL
eISSN
1791-7530
Externe Identifier
  • Clarivate Analytics Document Solution ID: 148GR
  • PubMed Identifier: 23645726
ISSN
0250-7005
Ausgabe der Veröffentlichung
5
Zeitschrift
ANTICANCER RESEARCH
Schlüsselwörter
  • Artesunate
  • cancer
  • safety study
  • dog
  • comparative oncology
Paginierung
1819 - 1827
Datum der Veröffentlichung
2013
Status
Published
Titel
Safety and Efficacy Field Study of Artesunate for Dogs with Non-resectable Tumours
Sub types
  • Article
Ausgabe der Zeitschrift
33

Data source: Web of Science (Lite)

Other metadata sources:
Abstract
The anti-malarial drug artesunate has shown anticancer activity in vitro and in preliminary animal experiments, but experience in patients with cancer is very limited. Pre-clinical studies in dogs indicated morbidity at high dosage levels. This study evaluated the effects of artesunate in canine cancer cell lines and in canine cancer patients. Four canine cell lines were tested in vitro for sensitivity towards artesunate and dihydroartemisinin (DHA; active metabolite of artesunate). The half-maximal inhibitory concentration (IC50) values for artesunate or DHA were 2-60 μM in three cell lines, while one cell line was much less sensitive to artesunate (IC50 337 μM) than to DHA (IC50 50 μM). A safety/efficacy field study with artesunate was conducted in 23 dogs with non-resectable tumours. Artesunate was administered for 7-385 days at a dosage of 651-1178 (median 922) mg/m(2). No neurological or cardiac toxicity was observed and seven dogs exhibited no adverse effects at all. Fever and haematological/gastrointestinal toxicity, mostly transient, occurred in 16 dogs. One dog died from pneumonia. Plasma artesunate and DHA levels fell below the limit of detection within 8-12 h after artesunate administration, while levels after two hours were close to 1 μM. Artesunate produced a long-lasting complete remission in one case of cancer and short-term stabilization of another seven cases.
Addresses
  • Department of Clinical Sciences of Companion Animals, Faculty of Veterinary Medicine, PO Box 80.154, University of Utrecht, 3508 TD Utrecht, The Netherlands. G.R.Rutteman@uu.nl
Autoren
  • Gerard R Rutteman
  • Suzanne A Erich
  • Jan A Mol
  • Bart Spee
  • Guy CM Grinwis
  • Lawrence Fleckenstein
  • Cheryl A London
  • Thomas Efferth
eISSN
1791-7530
Externe Identifier
  • PubMed Identifier: 23645726
Open access
false
ISSN
0250-7005
Ausgabe der Veröffentlichung
5
Zeitschrift
Anticancer research
Schlüsselwörter
  • Tumor Cells, Cultured
  • Animals
  • Dogs
  • Lymphoma
  • Carcinoma, Squamous Cell
  • Mouth Neoplasms
  • Dog Diseases
  • Artemisinins
  • Antimalarials
  • Treatment Outcome
  • Cell Proliferation
  • Artesunate
Sprache
eng
Medium
Print
Paginierung
1819 - 1827
Datum der Veröffentlichung
2013
Status
Published
Datum der Datenerfassung
2013
Titel
Safety and efficacy field study of artesunate for dogs with non-resectable tumours.
Sub types
  • Research Support, Non-U.S. Gov't
  • Journal Article
Ausgabe der Zeitschrift
33

Data source: Europe PubMed Central

Abstract
The anti-malarial drug artesunate has shown anticancer activity in vitro and in preliminary animal experiments, but experience in patients with cancer is very limited. Pre-clinical studies in dogs indicated morbidity at high dosage levels. This study evaluated the effects of artesunate in canine cancer cell lines and in canine cancer patients. Four canine cell lines were tested in vitro for sensitivity towards artesunate and dihydroartemisinin (DHA; active metabolite of artesunate). The half-maximal inhibitory concentration (IC50) values for artesunate or DHA were 2-60 μM in three cell lines, while one cell line was much less sensitive to artesunate (IC50 337 μM) than to DHA (IC50 50 μM). A safety/efficacy field study with artesunate was conducted in 23 dogs with non-resectable tumours. Artesunate was administered for 7-385 days at a dosage of 651-1178 (median 922) mg/m(2). No neurological or cardiac toxicity was observed and seven dogs exhibited no adverse effects at all. Fever and haematological/gastrointestinal toxicity, mostly transient, occurred in 16 dogs. One dog died from pneumonia. Plasma artesunate and DHA levels fell below the limit of detection within 8-12 h after artesunate administration, while levels after two hours were close to 1 μM. Artesunate produced a long-lasting complete remission in one case of cancer and short-term stabilization of another seven cases.
Autoren
  • Gerard R Rutteman
  • Suzanne A Erich
  • Jan A Mol
  • Bart Spee
  • Guy CM Grinwis
  • Lawrence Fleckenstein
  • Cheryl A London
  • Thomas Efferth
Autoren-URL
https://www.ncbi.nlm.nih.gov/pubmed/23645726
eISSN
1791-7530
Ausgabe der Veröffentlichung
5
Zeitschrift
Anticancer Res
Schlüsselwörter
  • Artesunate
  • cancer
  • comparative oncology
  • dog
  • safety study
  • Animals
  • Antimalarials
  • Artemisinins
  • Artesunate
  • Carcinoma, Squamous Cell
  • Cell Proliferation
  • Dog Diseases
  • Dogs
  • Lymphoma
  • Mouth Neoplasms
  • Treatment Outcome
  • Tumor Cells, Cultured
Sprache
eng
Country
Greece
Paginierung
1819 - 1827
PII
33/5/1819
Datum der Veröffentlichung
2013
Status
Published
Datum, an dem der Datensatz öffentlich gemacht wurde
2013
Titel
Safety and efficacy field study of artesunate for dogs with non-resectable tumours.
Sub types
  • Journal Article
  • Research Support, Non-U.S. Gov't
Ausgabe der Zeitschrift
33

Data source: PubMed

Beziehungen:
Property of

Tools